Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Anita Zahlten-Kumeli
Once- Versus Twice-Weekly Carfilzomib in Relapsed and Refractory Multiple Myeloma by Select Patient Characteristics: Phase 3 A.R.R.O.W. Study Subgroup Analysis
Blood Cancer Journal
Oncology
Hematology
Related publications
Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Study
American Journal of Hematology
Hematology
Isatuximab Plus Carfilzomib/Dexamethasone Versus Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: IKEMA Phase III Study Design
Future Oncology
Medicine
Cancer Research
Oncology
Carfilzomib for Relapsed or Refractory Multiple Myeloma
The Lancet Oncology
Oncology
Carfilzomib Monotherapy in Japanese Patients With Relapsed or Refractory Multiple Myeloma: A Phase 1/2 Study
Cancer Science
Cancer Research
Medicine
Oncology
Emerging Role of Carfilzomib in Treatment of Relapsed and Refractory Lymphoid Neoplasms and Multiple Myeloma
Core Evidence
Medicine
Reviews
References
Pharmacology
Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
Cancers
Cancer Research
Oncology
Daratumumab-Based Regimens Are Highly Effective and Well Tolerated in Relapsed or Refractory Multiple Myeloma Regardless of Patient Age: Subgroup Analysis of the Phase 3 CASTOR and POLLUX Studies
Haematologica
Hematology
A Phase I/Ii Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
Clinical Cancer Research
Cancer Research
Oncology
Study of Twice-Weekly Injections of Teriparatide by Comparing Efficacy With Once-Weekly Injections in Osteoporosis Patients: The TWICE Study
Osteoporosis International
Medicine
Endocrinology
Metabolism
Diabetes
